NEW YORK (GenomeWeb) – With a string of deals, including its most recent with healthcare software developer Allscripts, NantHealth is aiming to make precision oncology a reality in the near future.

Earlier this week, Allscripts said that it had invested $200 million in NantHealth for a 10 percent stake. For NantHealth, the Allscripts deal provides the firm a chance to show Wall Street that it can link diverse technologies and data sources to bring precision medicine to a large swath of the US population.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.